Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
- 123 Downloads
We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer.
Patients and methods
Patients with advanced esophageal and gastroesophageal junction cancer were enrolled. All gave informed consent. They were initially treated with paclitaxel 90 mg/m2 intravenously on Day 1 and bryostatin-1 50 μg/m2 on Day 2 weekly for three consecutive weeks out of four. Because of severe myalgias, dosing was reduced to paclitaxel 80 mg/m2 with bryostatin-1 40 μg/m2 and then to paclitaxel 80 mg/m2 with bryostatin-1 25 μg/m2.
Twenty-four patients were enrolled, with 22 assessable for response. The partial response rate was 27%. 10 patients treated with bryostatin-1 40–50 μg/m2 had a response rate of 40 versus 17% at bryostatin-1 25 μg/m2 (p-value = 0.3). Median time-to-progression was 3.7 months and median survival was 8.3 months. Grade 3/4 myalgias were seen in 50% of patients. Myalgias appeared to be related to bryostatin-1 dose. Because of toxicity, the trial was closed prior to full accrual.
Despite potential anti-tumor activity of this combination in patients with advanced esophageal cancer, further development is not warranted, given the severe toxicity, especially myalgias, that were seen.
KeywordsBryostatin-1 Esophageal cancer Gastroesophageal cancer Paclitaxel Protein kinase C
Supported in part by FDA-R01-001826 from the Food and Drug Administration Orphan Drug Program (to GKS).
- 1.Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A (2006) A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 24:353–357PubMedCrossRefGoogle Scholar
- 5.Grant S, Jarvis WD, Swerdlow PS, Turner AJ, Traylor RS, Wallace HJ, Lin PS, Pettit GR, Gewirtz DA (1992) Potentiation of the activity of 1–beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL–60 cells: association with enhanced fragmentation of mature DNA. Cancer Res 52:6270–6278PubMedGoogle Scholar
- 12.Kaubisch A, Kelsen D, Saltz L, Kemeny N, O’Reilly E, Ilson D, Endres S, Barazzuol J, Schwartz G (1999) A pase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors. Proc Amer Soc Clin Onc 18:166a (Abstract 639)Google Scholar
- 16.National Cancer Institute (1999) NCI, Common Toxicity Criteria, version 2.0,. BethesdaGoogle Scholar
- 19.Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, et al. (1993) Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85:1812–1818PubMedCrossRefGoogle Scholar